The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States

被引:67
作者
Lee, Yi-Te [1 ,2 ]
Wang, Jasmine J. [2 ,3 ]
Luu, Michael [4 ]
Noureddin, Mazen [5 ,6 ]
Kosari, Kambiz [6 ]
Agopian, Vatche G. [7 ,8 ]
Rich, Nicole E. [9 ]
Lu, Shelly C. [3 ,5 ]
Tseng, Hsian-Rong [1 ,2 ]
Nissen, Nicholas N. [3 ,6 ]
Singal, Amit G. [9 ]
Yang, Ju Dong [3 ,5 ,6 ]
机构
[1] Univ Calif Los Angeles, Calif NanoSyst Inst, Crump Inst Mol Imaging, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[4] Cedars Sinai Med Ctr, Biostat & Bioinformat Res Ctr, Los Angeles, CA 90048 USA
[5] Cedars Sinai Med Ctr, Karsh Div Gastroenterol & Hepatol, 8900 Beverly Blvd, Los Angeles, CA 90048 USA
[6] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA 90048 USA
[7] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA
[8] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[9] Univ Texas Southwestern Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2021年 / 113卷 / 11期
基金
美国国家卫生研究院;
关键词
HEPATITIS-C VIRUS; HEPATOCELLULAR-CARCINOMA; HEALTH; PROGNOSIS; BURDEN; RATES;
D O I
10.1093/jnci/djab079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Recent trends of hepatocellular carcinoma (HCC) mortality and outcome remain unknown in the United States. We investigated the recent trends of primary liver cancer (excluding intrahepatic cholangiocarcinoma) mortality and HCC stage, treatment, and overall survival (OS) in the United States. Methods: The National Center for Health Statistics Database was analyzed to investigate the trend of primary liver cancer mortality. We analyzed the Surveillance, Epidemiology, and End Results 18 Database to assess the temporal trend of tumor size, stage, treatment, and OS of HCC. We investigated the association between HCC diagnosis year and OS using Cox regression analysis. All statistical tests were 2-sided. Results: During 2000-2018, liver cancer mortality rates increased until 2013, plateaued during 2013-2016 (annual percent change = 0.1%/y, 95% confidence interval [CI] = -2.1%/y to 2.4%/y, P = .92), and started to decline during 2016-2018 (annual percent change = -1.5%/y, 95% CI = -3.2%/y to 0.2%/y, P = .08). However, mortality continues to increase in American Indian and Alaska Native, individuals aged 65 years or older, and in 33 states. There was a 0.61% (95% CI = 0.53% to 0.69%, P < .001) increase in localized stage HCC and a 0.86-mm (95% CI = -1.10 to -0.62 mm, P < .001) decrease in median tumor size per year. The 1-year OS rate increased from 36.3% (95% CI = 34.3% to 38.3%) to 58.1% (95% CI = 56.9% to 59.4%) during 2000-2015, and the 5-year OS rate almost doubled from 11.7% (95% CI = 10.4% to 13.1%) to 21.3% (95% CI = 20.2% to 22.4%) during 2000-2011. Diagnosis year (per year) (adjusted hazard ratio = 0.96, 95% CI = 0.96 to 0.97) was independently associated with OS in multivariable analysis. Conclusions: Primary liver cancer mortality rates have started to decline in the United States with demographic and state-level variation. With an increasing detection of localized HCC, the OS of HCC has improved over the past decades.
引用
收藏
页码:1531 / 1541
页数:11
相关论文
共 47 条
[1]  
Allaire M, 2020, JHEP REP, V2, DOI 10.1016/j.jhepr.2020.100134
[2]   Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States [J].
Altekruse, Sean F. ;
Henley, S. Jane ;
Cucinelli, James E. ;
McGlynn, Katherine A. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (04) :542-553
[3]  
Alvidrez J, 2019, AM J PUBLIC HEALTH, V109, pS16, DOI [10.2105/ajph.2018.304883, 10.2105/AJPH.2018.304883]
[4]  
Anderson R N, 1998, Natl Vital Stat Rep, V47, P1
[5]  
[Anonymous], 2016, Applied Regression Analysis and Generalized Linear Models
[6]  
[Anonymous], JOINPOINT REGRESSION
[7]   Hepatitis C-Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals [J].
Beste, Lauren A. ;
Green, Pamela ;
Berry, Kristin ;
Belperio, Pamela ;
Ioannou, George N. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (10) :1003-1005
[8]   Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer [J].
Chang, Mei-Hwei ;
You, San-Lin ;
Chen, Chien-Jen ;
Liu, Chun-Jen ;
Lai, Ming-Wei ;
Wu, Tzee-Chung ;
Wu, Shu-Fen ;
Lee, Chuan-Mo ;
Yang, Sheng-Shun ;
Chu, Heng-Cheng ;
Wang, Tsang-Eng ;
Chen, Bor-Wen ;
Chuang, Wan-Long ;
Soon, Maw-Soan ;
Lin, Ching-Yih ;
Chiou, Shu-Ti ;
Kuo, Hsu-Sung ;
Chen, Ding-Shinn .
GASTROENTEROLOGY, 2016, 151 (03) :472-+
[9]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[10]   Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis [J].
Choi, Debra T. ;
Kum, Hye-Chung ;
Park, Sulki ;
Ohsfeldt, Robert L. ;
Shen, Yu ;
Parikh, Neehar D. ;
Singal, Amit G. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (05) :976-+